Anti-Mouse CD3 (Clone 17A2) – Recombinant in vivo Functional Grade

γ/δ TCR-positive T-T hybridoma D1

This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.ltration.

Recombinant antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Next Day 2-8°C

PhenoCycler-Fusion (CODEX)®
FA^2,3,5,6
Depletion^2,4,5
IP⁶
RIA⁶
IHC (Frozen) The suggested concentration for this 17A2 antibody in IHC staining on frozen tissue is 5.0 - 10 μg per ml. Titration of the reagent is recommended for optimal performance for each application.

17A2 activity is directed against the mouse TCR ⍺β- and TCR γ𝛿-associated CD3 molecular complex via the CD3ε chain.

CD3 is an invariant antigen of the T cell receptor (TCR) ¹. The CD3/TCR complex is composed of a ⍺β or γ𝛿 TCR heterodimer noncovalently associated with invariant CD3 dimers 𝜀γ, 𝜀𝛿, and 𝜁𝜁 in a 1:1:1:1 stoichiometry. The TCR mediates recognition of antigenic peptides bound to major histocompatibility complex (MHC) molecules on antigen-presenting cells, while the CD3 portion of the complex transduces activation signals to the T cell nucleus. Together, TCR and CD3 molecules initiate protective immunity against microbes and cancers.

17A2 has been explored as a treatment against graft-versus-host disease ^2,3. 17A2 leads to T cell depletion in vivo that is associated with a significant reduction in B cell population ⁴. Additionally, 17A2 is less mitogenic that some other anti-CD3 antibodies (i.e., 145-2C11 hamster IgG and KT3 rat IgG2a) ³. FcγRI may be involved in 17A2 activity ⁵.

17A2 was generated by immunizing female Sprague-Dawley rats with homogenized γ𝛿 TCR⁺ T-T hybridoma cells (D1 line) ⁶. The resulting rat cells were fused to P3X63-Ag8-653 non-secreting mouse myeloma cells and hybridomas were screened for the secretion of IL-2 in the presence of D1 cells.

CD3 is expressed on T cells.

Peptide antigen/MHC-complex

Antigen recognition, TCR signal transduction, T cell activation

1. Mariuzza RA, Agnihotri P, Orban J. J Biol Chem. 295(4):914-925. 2020.
2. Mysliwietz J, Thierfelder S. Blood. 80(10):2661-2667. 1992.
3. Vossen AC, Tibbe GJ, Kroos MJ, et al. Eur J Immunol. 25(6):1492-1496. 1995.
4. Loubaki L, Tremblay T, Bazin R. J Immunol Methods. 393(1-2):38-44. 2013.
5. Kummer U, Zengerle U, Pischel J, et al. Immunol Lett. 75(2):153-158. 2001.
6. Miescher GC, Schreyer M, MacDonald HR. Immunol Lett. 23(2):113-118. 1989.